Skip to content

Kodiak Sciences Inc KOD Operating Cash Flow

Operating Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.08B+3.2%
HRO
HarrowHROW
-$8.99M-146%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.65M-29.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$65.99M-47.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$60.58M-146%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$106.5M-95.8%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's operating cash flow?
Kodiak Sciences Inc (KOD) reported operating cash flow of -$40.01M in Q1 2026.
How has Kodiak Sciences Inc's operating cash flow changed year-over-year?
Kodiak Sciences Inc's operating cash flow decreased by 37.6% year-over-year, from -$29.08M to -$40.01M.
What is the long-term trend for Kodiak Sciences Inc's operating cash flow?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's operating cash flow has grown at a -7.1% compound annual growth rate (CAGR), from -$182.27M to -$136.01M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.